Niemann-Pick Type C 1 (NPC1) and NPC2 Gene Variability in Demented Patients with Evidence of Brain Amyloid Deposition

• Published in: Journal of Alzheimer's disease Vol. 83; no. 3; p. 1313
• Main Authors: Sorrentino, Federica, Arighi, Andrea, Serpente, Maria, Arosio, Beatrice, Arcaro, Marina, Visconte, Caterina, Rotondo, Emanuela, Vimercati, Roberto, Ferri, Evelyn, Fumagalli, Giorgio G, Pietroboni, Anna M, Carandini, Tiziana, Scarpini, Elio, Fenoglio, Chiara, Galimberti, Daniela
• Format: Journal Article
• Language: English
• Published: Netherlands 01-01-2021
• Subjects: Aged; Amyloid beta-Peptides - cerebrospinal fluid; Brain - pathology; Dementia - genetics; Dementia - psychology; Female; High-Throughput Nucleotide Sequencing; Humans; Male; Niemann-Pick C1 Protein - genetics; Peptide Fragments - cerebrospinal fluid; Phenotype; Positron-Emission Tomography; Vesicular Transport Proteins - genetics; Niemann-Pick Type C; NPC1; NPC2; cerebrospinal fluid; Amyloid; variability; psychiatric onset
• ISSN: 1875-8908
• DOI: 10.3233/JAD-210453

Variants in Niemann-Pick Type C genes (NPC1 and NPC2) have been suggested to play a role as risk or disease modifying factors for Alzheimer's disease (AD).
The aim of this study was to analyze NPC1 and NPC2 variability in demented patients with evidence of brain amyloid-β 1-42 (Aβ) deposition and to correlate genetic data with clinical phenotypes.
A targeted Next Generation Sequencing panel was customized to screen NPC1, NPC2, and main genes related to neurodegenerative dementias in a cohort of 136 demented patients with cerebrospinal fluid (CSF) low Aβ levels or positive PET with Aβ tracer and 200 non-demented geriatric subjects.
Seven patients were carriers of NPC variants in heterozygosis. Four of them displayed pathogenic variants previously found in NPC patients and one AD patient had a novel variant. The latter was absent in 200 non-demented elderly subjects. Five of seven patients (70%) exhibited psychiatric symptoms at onset or later as compared with 43%in non-carriers (p > 0.05).
The frequency of NPC1 and NPC2 heterozygous variants in patients with CSF evidence of Aβ deposition is higher than in the general population.